Paul E. Sax
Impact in
- Virology top 0.05%
- HIV Research and Treatment
- Emergency Medicine top 0.02%
- HIV-related health complications and treatments
Papers in
-
- HIV/AIDS drug development and treatment 99
- HIV/AIDS Research and Interventions 52
- Virology 55
- HIV Research and Treatment 55
- Co-authors
- Eric Rosenberg (7 shared papers)Rajesh T. Gandhi (12 shared papers)Bruce D. Walker (5 shared papers)Rochelle P. Walensky (29 shared papers)Steven Boswell (2 shared papers)Spyros A. Kalams (1 shared paper)Angela M. Caliendo (1 shared paper)James M. Billingsley (1 shared paper)
- Journals
- Clinical Infectious Diseases (50 papers)Open Forum Infectious Diseases (17 papers)JAIDS Journal of Acquired Immune Deficiency Syndromes (17 papers)The Journal of Infectious Diseases (13 papers)AIDS (11 papers)
- Partner nations
- United StatesUnited KingdomFrance
In The Last Decade
Paul E. Sax
234 papers receiving 14.0k citations
Paul E. Sax's Hit Papers
Peers
Comparison fields: 5 of 167
- Virology 4.6k
- Emergency Medicine 3.8k
- Infectious Diseases 7.4k
- Epidemiology 2.3k
- Hepatology 516
Countries citing papers authored by Paul E. Sax
This map shows the geographic impact of Paul E. Sax's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul E. Sax with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul E. Sax more than expected).
Fields of papers citing papers by Paul E. Sax
This network shows the impact of papers produced by Paul E. Sax. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul E. Sax. The network helps show where Paul E. Sax may publish in the future.
Co-authors
The 25 scholars most cited alongside Paul E. Sax, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 244 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Vigorous HIV-1-Specific CD4 + T Cell Responses Associated with Control of Viremia Hit paper breakdown → | 1997 | 1517 |
| 2 | Metabolic Abnormalities and Cardiovascular Disease Risk Factors in Adults with Human Immunodeficiency Virus Infection and Lipodystrophy Hit paper breakdown → | 2001 | 550 |
| 3 | Transmission of SARS-CoV-2: A Review of Viral, Host, and Environmental Factors Hit paper breakdown → | 2020 | 486 |
| 4 | Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults Hit paper breakdown → | 2016 | 483 |
| 5 | Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials Hit paper breakdown → | 2019 | 479 |
| 6 | 2006 | 421 | |
| 7 | Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults Hit paper breakdown → | 2018 | 403 |
| 8 | Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202 Hit paper breakdown → | 2011 | 384 |
| 9 | 2012 | 341 | |
| 10 | Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults Hit paper breakdown → | 2022 | 340 |
| 11 | 2006 | 330 | |
| 12 | 2001 | 316 | |
| 13 | 2020 | 312 | |
| 14 | Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial Hit paper breakdown → | 2017 | 287 |
| 15 | 2008 | 274 | |
| 16 | 2014 | 273 | |
| 17 | 2000 | 269 | |
| 18 | 2007 | 235 | |
| 19 | 2009 | 215 | |
| 20 | 2009 | 206 |
About Paul E. Sax
Paul E. Sax is a scholar working on Infectious Diseases, Virology, Emergency Medicine, Epidemiology and Hepatology, having authored 244 papers that have together received 14.3k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (99 papers), HIV-related health complications and treatments (55 papers), HIV Research and Treatment (55 papers), HIV/AIDS Research and Interventions (52 papers), Hepatitis C virus research (10 papers), Pneumocystis jirovecii pneumonia detection and treatment (10 papers), Cytomegalovirus and herpesvirus research (7 papers) and Pharmacological Effects and Toxicity Studies (7 papers). The work is most often cited by research in Virology (4.6k citations), Emergency Medicine (3.8k citations), Infectious Diseases (7.4k citations), Epidemiology (2.3k citations) and Hepatology (516 citations). Paul E. Sax has collaborated with scholars based in United States, United Kingdom and France. Frequent co-authors include Eric Rosenberg, Rajesh T. Gandhi, Bruce D. Walker, Rochelle P. Walensky, Steven Boswell, Spyros A. Kalams, Angela M. Caliendo, James M. Billingsley, Kenneth A. Freedberg and Bruce R. Schackman. Their work appears in journals such as Clinical Infectious Diseases, Open Forum Infectious Diseases, JAIDS Journal of Acquired Immune Deficiency Syndromes, The Journal of Infectious Diseases and AIDS.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.